Barcelona, July 14th 2020
CORDIS recognizes the European model of citizen participation for the early detection of Alzheimer's
• The European Commission has highlighted the MOPEAD project, coordinated in Spain by Fundació ACE, in an article published on its research news platform
• The project has designed four strategies to detect hidden cases of dementia by applying innovative technologies such as Big Data
The European project MOPEAD (Models of Patient Engagement for Alzheimer's Disease), coordinated in Spain by Fundació ACE - Barcelona Alzheimer & Treatment & Research Center and launched by the European Federation of Pharmaceutical Industry Associations (EFPIA) and the European Union through the consortium IMI (Innovative Medicines Initiative) has been highlighted in an article published by CORDIS, the European Commission's research news platform.
Under the title "Diagnosis of hidden Alzheimer's disease", the article details the four models designed within the framework of this project to promote citizen participation in the early detection of dementia and thus discover hidden cases of dementia: answering an online questionnaire, voluntarily participating in a medical examination at Fundació ACE and undergoing primary and tertiary care tests.
Dr. Mercè Boada, medical director of Fundació ACE and coordinator of the project, says that "the experience with the MOPEAD project has been very positive. It is essential to find new ways to advance in the detection of Alzheimer's in mild phases". Dr. Boada also points out that "the digital technology and Big Data developed by the project's technological partner, GMV, have been fundamental for attracting patients by means of online marketing strategies and for extracting clinical evidence; they have done an extraordinary job".
A wide variety of organizations have taken part in the MOPEAD project: Fundació ACE - Barcelona Alzheimer Treatment & Research Center, Eli Lilly Company Ltd, ASDM Consulting, AstraZeneca AB, European Institute of Women's Health, GMV Soluciones Globales Internet S.A.U, Karolinska Institute, KITE Innovation (Europe) Ltd, Spomincica- Alzheimer Slovenia, Cologne University Hospital, Ljubljana University Medical Center, Fundació Hospital Universitari Vall d'Hebron- Institut de Recerca, Stichting VUmc and Alzheimer Europe.
The patient in the early detection of Alzheimer's
The main objective of MOPEAD is to consolidate a system that allows the early diagnosis of dementia, through the collaboration and complicity of society, in order to define new therapeutic interventions that help to stop Alzheimer's disease. Currently, dementia affects 50 million people globally, a figure that is expected to reach 152 million by 2050. In view of the need to tackle this disease, which affects more and more people around the world and for which there are still no effective treatments or cures, in recent years experts have focused on early detection of Alzheimer's, since it is at this stage that intervention can be most effective.
More information on this link.